Abstract Background Enfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized. Material and methods We conducted a retrospective cohort study of patients wit...
Luis Angel Diaz Tejada, Fabiana Alexandra Príncipe Osorio, A. Attia et al.· The Oncologist· 0 citations
Introduction Trastuzumab deruxtecan (T-DXd) has transformed treatment for HER2-expressing malignancies, yet pneumonitis remains a potentially fatal toxicity. Most pneumonitis data derive from breast cancer cohorts, but risk factors and outcomes in non-breast solid organ tumors are poorly characterized. Materials and Me...
A. Attia, Jose Carlos Tuesta Delgado, Alexia Dayan Lecaros Zavalla et al.· Journal of Immunotherapy and...· 0 citations
This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.